Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Annie YoshiyamaSVP, Finance | Allogene TherapeuticsALLO | Open-market sale | 04/21 | 04/23 | 9,586 sh | $2.31 | $22,143.66 | −7.1% |
Beneski Benjamin MachinasSVP, Chief Technical Officer | Allogene TherapeuticsALLO | Open-market sale | 03/31 | 04/02 | 2,867 sh | $2.50 | $7,167.5 | −1.4% |
Chang David D.President and CEO | Allogene TherapeuticsALLO | Open-market sale | 03/16 | 03/18 | 47,763 sh | $2.47 | $117,974.61 | −0.9% |
Beneski Benjamin MachinasSVP, Chief Technical Officer | Allogene TherapeuticsALLO | Open-market sale | 03/16 | 03/18 | 4,835 sh | $2.47 | $11,942.45 | −2.4% |
Beneski Benjamin MachinasSVP, Chief Technical Officer | Allogene TherapeuticsALLO | Open-market sale | 03/02 | 03/04 | 7,132 sh | $2.60 | $18,543.2 | −3.4% |
Douglas Earl MartinSVP, General Counsel | Allogene TherapeuticsALLO | Open-market sale | 02/02 | 02/04 | 22,900 sh | $1.76 | $40,304 | −3.9% |
Allogene TherapeuticsALLO | Open-market sale | 02/02 | 02/04 | 24,001 sh | $1.76 | $42,241.76 | −1.9% | |
Chang David D.President and CEO | Allogene TherapeuticsALLO | Open-market sale | 02/02 | 02/04 | 95,269 sh | $1.80 | $171,484.2 | −1.8% |
Annie YoshiyamaSVP, Finance | Allogene TherapeuticsALLO | Open-market sale | 02/02 | 02/04 | 4,167 sh | $1.72 | $7,167.24 | −3.1% |
Roberts ZacharyEVP of R&D | Allogene TherapeuticsALLO | Open-market sale | 02/02 | 02/04 | 35,700 sh | $1.77 | $63,189 | −5.8% |
Beneski Benjamin MachinasSVP, Chief Technical Officer | Allogene TherapeuticsALLO | Open-market sale | 02/02 | 02/04 | 7,549 sh | $1.73 | $13,059.77 | −3.5% |
Roberts ZacharyEVP of R&D | Allogene TherapeuticsALLO | Open-market sale | 01/21 | 01/23 | 26,269 sh | $1.56 | $40,979.64 | −4.1% |
Beneski Benjamin MachinasSVP, Chief Technical Officer | Allogene TherapeuticsALLO | Open-market sale | 25/11/17 | 25/11/19 | 786 sh | $1.22 | $958.92 | −0.4% |
Allogene TherapeuticsALLO | Open-market sale | 25/10/21 | 25/10/23 | 36,744 sh | $1.26 | $46,297.44 | −2.8% | |
Deborah M. MessemerDirector | Allogene TherapeuticsALLO | Open-market sale10b5-1 plan | 25/06/10 | 25/06/12 | 36,885 sh | $1.42 | $52,376.7 | −25.6% |
Annie YoshiyamaSVP, Finance | Allogene TherapeuticsALLO | Open-market sale | 25/04/21 | 25/04/23 | 9,601 sh | $1.41 | $13,537.41 | −6.8% |
Chang David D.President and CEO | Allogene TherapeuticsALLO | Open-market sale | 25/03/14 | 25/03/18 | 46,668 sh | $1.96 | $91,469.28 | −0.9% |
Beneski Benjamin MachinasSVP, Chief Technical Officer | Allogene TherapeuticsALLO | Open-market sale | 25/03/14 | 25/03/18 | 5,488 sh | $1.98 | $10,866.24 | −2.5% |
Deborah M. MessemerDirector | Allogene TherapeuticsALLO | Open-market sale10b5-1 plan | 25/02/18 | 25/02/20 | 13,313 sh | $2.43 | $32,350.59 | −8.4% |
Douglas Earl MartinSVP, General Counsel | Allogene TherapeuticsALLO | Open-market sale | 25/02/03 | 25/02/05 | 6,404 sh | $1.71 | $10,950.84 | −1.1% |